Approaches to vaccination against coronavirus infection in patients with autoimmune inflammatory rheumatic diseases

Abstract

The problem of COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases is discussed. There is an increased risk of viral infections in these patients. Attending physicians should provide patients with rheumatic diseases with complete information about the risks and benefits of COVID-19 immunoprophylaxis. The use of immunosuppressive drugs, rather than the diseases themselves, can reduce the level of post-vaccination immune response. This requires choosing the optimal time for carrying out COVID-19 vaccination in this group of patients. Fragments of European and American recommendations on vaccination against COVID-19 in patients with rheumatic diseases are given.

Keywords:COVID-19; vaccination; autoimmune inflammatory rheumatic diseases; immunosuppressants

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

Contribution. Concept and design of the research – Tarasova А.А., Kostinov М.Р., Kvasova М.А., collection and processing of material, writing – Tarasova А.А., editing, approval of the final version of the article – Kostinov М.Р., responsibility for the integrity of all parts of the article – Kvasova М.А.

For citation: Tarasova A.A., Kostinov M.P., Kvasova M.A. Approaches to vaccination against coronavirus infection in patients with autoimmune inflammatory rheumatic diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (4): 118–26. DOI: https://doi.org/10.33029/2305-3496-2022-11-4-118-126

References

1. Furer V., Rondaan C,. Heijstek M., et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5 (2): e001041. DOI: https://doi.org/10.1136/rmdopen-2019-001041 PMID: 31673420; PMCID: PMC6803008.

2. Curtis J.R., Johnson S.R., Anthony D.D., et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2. Arthritis Rheumatol. 2021; 73 (8): e30–45. DOI: https://doi.org/10.1002/art.41877

3. Rondaan C., Furer V., Heijstek M.W., et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019; 5 (2): e001035. DOI: https://doi.org/10.1136/rmdopen-2019-001035 PMID: 31565247; PMCID: PMC6744079.

4. Furer V., Rondaan C., Heijstek M.W., et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79 (1): 39–52. DOI: https://doi.org/10.1136/annrheumdis-2019-215882

5. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, first issued 25 January 2021, updated 15 June 2021. URL: WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.2-rus.pdf; https://apps.who.int/iris/handle/10665/342147

6. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing interim guidance. First issued 8 January 2021. Updated 15 June 2021. URL: https://apps.who.int/iris/handle/10665/341786

7. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience): interim guidance, first issued 10 February 2021, updated 21 April 2021. URL: https://apps.who.int/iris/handle/10665/341190

8. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine: interim guidance, first issued 17 March 2021, updated 15 June 2021. URL: https://apps.who.int/iris/handle/10665/341784

9. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, 24 May 2021. URL: https://apps.who.int/iris/handle/10665/341829

10. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: interim guidance, 7 May 2021. URL: https://apps.who.int/iris/handle/10665/341534

11. Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm Grading of evidence. Evidence to recommendation tables 7 May 2021. URL: https://apps.who.int/iris/handle/10665/341829

12. Background document to the WHO Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19, developed by Oxford University and AstraZeneca 1 March 2021. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-AZD1222-GRADE-ETR-2021.1.

13. Background document to the WHO Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac 24 May 2021. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-GRADE-TR

14. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy BNT162b2mRNA COVID-19. Clinical Trial Group. N Engl J Med. 2020; 383 (27): 2603–15. DOI: https://doi.org/10.1056/NEJMoa2034577

15. CDC Vaccination Considerations for Persons with Underlying Medical Conditions. 2020. URL: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/underlying-conditions.html (date of access January 13, 2021)

16. Priori R., Pellegrino G., Colafrancesco S., et al. SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis. 2021; 80 (7): 953–4. DOI: https://doi.org/10.1136/annrheumdis-2021-220059 Epub 2021 Feb 23. PMID: 33622689.

17. Park J.K., Lee E.B., Shin K., et al. Korean College of Rheumatology Task Force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: clinical guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021; 36 (12): e95. DOI: https://doi.org/10.3346/jkms.2021.36.e95

18.Santosa A., Xu C., Arkachaisri T., et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021; 24 (6): 746–57. DOI: https://doi.org/10.1111/1756-185X.14107

19. Lyubavina N.A., Saltsev S.G., Menkov N.V., Tyurikova L.V., Plastinina S.S., Shonia M.L., et al. Immunological approaches to the treatment of novel coronavirus infection (review). Sovrem Tehnologii Med. 2021; 13 (3): 81–99. DOI: https://doi.org/10.17691/stm2021.13.3.09

20. Principles for COVID-19 vaccination in musculoskeletal and rheumatology for clinicians. Arthritis and Musculoskeletal Alliance (Version 7, 9 June 2021). URL: www.arma.uk.net

21. Benucci M., Infantino M., Marotto D., et al. Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives. Clin Exp Rheumatol. 2021; 39 (1): 196–202.

22.Braun-Moscovici Y., Kaplan M., Braun M., et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80 (10): 1317–21. DOI: https://doi.org/10.1136/annrheumdis-2021-220503

23. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16 (8): 2825–33. DOI: https://doi.org/10.1200/JCO.1998.16.8.2825

24.Houot R., Levy R., Cartron G., Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020; 136: 4–6. DOI: https://doi.org/10.1016/j.ejca.2020.06.017

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»